252 related articles for article (PubMed ID: 26162948)
1. A Pound of Cure Requires An Ounce (or More) of Prevention: Survivorship and Complications of Therapy for Hematologic Malignancies.
Luskin MR; Banerjee R; Del Percio S; Loren AW
Curr Hematol Malig Rep; 2015 Sep; 10(3):225-36. PubMed ID: 26162948
[TBL] [Abstract][Full Text] [Related]
2. Total body irradiation, fludarabine, melphalan, and allogeneic hematopoietic stem cell transplantation for advanced pediatric hematologic malignancies.
Petropoulos D; Worth LL; Mullen CA; Madden R; Mahajan A; Choroszy M; Ha CS; Champlin RC; Chan KW
Bone Marrow Transplant; 2006 Mar; 37(5):463-7. PubMed ID: 16435013
[TBL] [Abstract][Full Text] [Related]
3. Survivorship in adolescents and young adults.
Kishtagari A; Tavakkoli M; Park JH
Acta Haematol; 2014; 132(3-4):383-90. PubMed ID: 25228564
[TBL] [Abstract][Full Text] [Related]
4. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
5. Reduced-intensity conditioned allogeneic haematopoietic stem cell transplantation results in durable disease-free and overall survival in patients with poor prognosis myeloid and lymphoid malignancies: eighty-month follow-up.
Patil S; Spencer A; Schwarer A; Lewis I; Hertzberg M; Avery S; Wei A; Noutsos T; Paul E; Taouk Y; Muirhead J
Bone Marrow Transplant; 2010 Jul; 45(7):1154-60. PubMed ID: 19898502
[TBL] [Abstract][Full Text] [Related]
6. Safety and outcome after fludarabine-thiotepa-TBI conditioning for allogeneic transplantation: a prospective study of 30 patients with hematologic malignancies.
van Besien K; Devine S; Wickrema A; Jessop E; Amin K; Yassine M; Maynard V; Stock W; Peace D; Ravandi F; Chen YH; Cheung T; Vijayakumar S; Hoffman R; Sosman J
Bone Marrow Transplant; 2003 Jul; 32(1):9-13. PubMed ID: 12815472
[TBL] [Abstract][Full Text] [Related]
7. CD52 and CD45 monoclonal antibodies for reduced intensity hemopoietic stem cell transplantation from HLA matched and one antigen mismatched unrelated donors.
Popat U; Carrum G; May R; Lamba R; Krance RA; Heslop HE; Brenner MK
Bone Marrow Transplant; 2005 Jun; 35(12):1127-32. PubMed ID: 15834432
[TBL] [Abstract][Full Text] [Related]
8. Sexual and reproductive health in cancer survivors.
Goldfarb S; Mulhall J; Nelson C; Kelvin J; Dickler M; Carter J
Semin Oncol; 2013 Dec; 40(6):726-44. PubMed ID: 24331193
[TBL] [Abstract][Full Text] [Related]
9. Psychological morbidities in adolescent and young adult blood cancer patients during curative-intent therapy and early survivorship.
Muffly LS; Hlubocky FJ; Khan N; Wroblewski K; Breitenbach K; Gomez J; McNeer JL; Stock W; Daugherty CK
Cancer; 2016 Mar; 122(6):954-61. PubMed ID: 26749023
[TBL] [Abstract][Full Text] [Related]
10. The use of second allogeneic hematopoietic stem cell transplantation for hematologic malignancies relapsed after the first: Does it worth to do?
Göksoy HS; Arat M
Transfus Apher Sci; 2016 Feb; 54(1):91-8. PubMed ID: 26976480
[TBL] [Abstract][Full Text] [Related]
11. Successful engraftment following allogeneic stem cell transplantation in very high-risk patients with busulfan as a single agent.
Bitan M; Or R; Shapira MY; Resnick IB; Ackerstein A; Samuel S; Elad S; Slavin S
Haematologica; 2005 Aug; 90(8):1089-95. PubMed ID: 16079108
[TBL] [Abstract][Full Text] [Related]
12. Psychological distress as a negative survival factor for patients with hematologic malignancies who underwent allogeneic hematopoietic stem cell transplantation.
Park JE; Kim KI; Yoon SS; Hahm BJ; Lee SM; Yoon JH; Shin WG; Lee HS; Oh JM
Pharmacotherapy; 2010 Dec; 30(12):1239-46. PubMed ID: 21114391
[TBL] [Abstract][Full Text] [Related]
13. Morbidity and Mortality Differences Between Hematopoietic Cell Transplantation Survivors and Other Cancer Survivors.
Chow EJ; Cushing-Haugen KL; Cheng GS; Boeckh M; Khera N; Lee SJ; Leisenring WM; Martin PJ; Mueller BA; Schwartz SM; Baker KS
J Clin Oncol; 2017 Jan; 35(3):306-313. PubMed ID: 27870568
[TBL] [Abstract][Full Text] [Related]
14. Outcome of Second Allogeneic Hematopoietic Cell Transplantation after Relapse of Myeloid Malignancies following Allogeneic Hematopoietic Cell Transplantation: A Retrospective Cohort on Behalf of the Grupo Español de Trasplante Hematopoyetico.
Orti G; Sanz J; Bermudez A; Caballero D; Martinez C; Sierra J; Cabrera Marin JR; Espigado I; Solano C; Ferrà C; García-Noblejas A; Jimenez S; Sampol A; Yañez L; García-Gutiérrez V; Pascual MJ; Jurado M; Moraleda JM; Valcarcel D; Sanz MA; Carreras E; Duarte RF
Biol Blood Marrow Transplant; 2016 Mar; 22(3):584-8. PubMed ID: 26631751
[TBL] [Abstract][Full Text] [Related]
15. A dose escalation study of total body irradiation followed by high-dose etoposide and allogeneic blood stem cell transplantation for the treatment of advanced hematologic malignancies.
Sobecks RM; Daugherty CK; Hallahan DE; Laport GF; Wagner ND; Larson RA
Bone Marrow Transplant; 2000 Apr; 25(8):807-13. PubMed ID: 10808200
[TBL] [Abstract][Full Text] [Related]
16. Coordination of Care in Survivorship After Treatment of Hematological Malignancies-The Journey is Not Over Yet.
Lee CJ; Muffly LS
Curr Hematol Malig Rep; 2017 Aug; 12(4):317-323. PubMed ID: 28534144
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcomes after allogeneic stem cell transplantation for children with hematological malignancies.
Ferry C; Gemayel G; Rocha V; Labopin M; Esperou H; Robin M; de Latour RP; Ribaud P; Devergie A; Leblanc T; Gluckman E; Baruchel A; Socié G
Bone Marrow Transplant; 2007 Aug; 40(3):219-24. PubMed ID: 17530002
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcome after allo-SCT: close follow-up on a large cohort treated with myeloablative regimens.
Abou-Mourad YR; Lau BC; Barnett MJ; Forrest DL; Hogge DE; Nantel SH; Nevill TJ; Shepherd JD; Smith CA; Song KW; Sutherland HJ; Toze CL; Lavoie JC
Bone Marrow Transplant; 2010 Feb; 45(2):295-302. PubMed ID: 19597425
[TBL] [Abstract][Full Text] [Related]
19. Update on non-myeloablative stem cell transplantation for hematologic malignancies.
Giralt S
Int J Hematol; 2002 Aug; 76 Suppl 1():368-75. PubMed ID: 12430884
[TBL] [Abstract][Full Text] [Related]
20. A pilot study of cytoreductive chemotherapy combined with infusion of additional peripheral blood stem cells reserved at time of harvest for transplantation in case of relapsed hematologic malignancies after allogeneic peripheral blood stem cell transplant.
Kim JG; Sohn SK; Kim DH; Lee NY; Suh JS; Lee KS; Lee KB
Bone Marrow Transplant; 2004 Jan; 33(2):231-6. PubMed ID: 14647258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
